184 related articles for article (PubMed ID: 23826874)
1. Reporter protein complementation imaging assay to screen and study Nrf2 activators in cells and living animals.
Ramkumar KM; Sekar TV; Foygel K; Elango B; Paulmurugan R
Anal Chem; 2013 Aug; 85(15):7542-9. PubMed ID: 23826874
[TBL] [Abstract][Full Text] [Related]
2. Pterostilbene-mediated Nrf2 activation: Mechanistic insights on Keap1:Nrf2 interface.
Bhakkiyalakshmi E; Dineshkumar K; Karthik S; Sireesh D; Hopper W; Paulmurugan R; Ramkumar KM
Bioorg Med Chem; 2016 Aug; 24(16):3378-86. PubMed ID: 27312421
[TBL] [Abstract][Full Text] [Related]
3. Implementation of a high-throughput screen for identifying small molecules to activate the Keap1-Nrf2-ARE pathway.
Wu KC; McDonald PR; Liu JJ; Chaguturu R; Klaassen CD
PLoS One; 2012; 7(10):e44686. PubMed ID: 23056183
[TBL] [Abstract][Full Text] [Related]
4. Development of Neh2-luciferase reporter and its application for high throughput screening and real-time monitoring of Nrf2 activators.
Smirnova NA; Haskew-Layton RE; Basso M; Hushpulian DM; Payappilly JB; Speer RE; Ahn YH; Rakhman I; Cole PA; Pinto JT; Ratan RR; Gazaryan IG
Chem Biol; 2011 Jun; 18(6):752-65. PubMed ID: 21700211
[TBL] [Abstract][Full Text] [Related]
5. Role of pterostilbene in attenuating immune mediated devastation of pancreatic beta cells via Nrf2 signaling cascade.
Sireesh D; Ganesh MR; Dhamodharan U; Sakthivadivel M; Sivasubramanian S; Gunasekaran P; Ramkumar KM
J Nutr Biochem; 2017 Jun; 44():11-21. PubMed ID: 28343084
[TBL] [Abstract][Full Text] [Related]
6. The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
Hori R; Yamaguchi K; Sato H; Watanabe M; Tsutsumi K; Iwamoto S; Abe M; Onodera H; Nakamura S; Nakai R
Cancer Med; 2019 Mar; 8(3):1157-1168. PubMed ID: 30735010
[TBL] [Abstract][Full Text] [Related]
7. Development of a cell-based high throughput luciferase enzyme fragment complementation assay to identify nuclear-factor-e2-related transcription factor 2 activators.
Xie W; Pao C; Graham T; Dul E; Lu Q; Sweitzer TD; Ames RS; Li H
Assay Drug Dev Technol; 2012 Dec; 10(6):514-24. PubMed ID: 22574653
[TBL] [Abstract][Full Text] [Related]
8. Combating oxidative stress in diabetic complications with Nrf2 activators: how much is too much?
Tan SM; de Haan JB
Redox Rep; 2014 May; 19(3):107-17. PubMed ID: 24559141
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2.
Ungvari Z; Bagi Z; Feher A; Recchia FA; Sonntag WE; Pearson K; de Cabo R; Csiszar A
Am J Physiol Heart Circ Physiol; 2010 Jul; 299(1):H18-24. PubMed ID: 20418481
[TBL] [Abstract][Full Text] [Related]
10. MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism.
Yang M; Yao Y; Eades G; Zhang Y; Zhou Q
Breast Cancer Res Treat; 2011 Oct; 129(3):983-91. PubMed ID: 21638050
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of redox-sensitive Nrf2-Keap1 pathway in diabetes.
Bhakkiyalakshmi E; Sireesh D; Rajaguru P; Paulmurugan R; Ramkumar KM
Pharmacol Res; 2015 Jan; 91():104-14. PubMed ID: 25447793
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of chemical activation of Nrf2.
Li Y; Paonessa JD; Zhang Y
PLoS One; 2012; 7(4):e35122. PubMed ID: 22558124
[TBL] [Abstract][Full Text] [Related]
13. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy.
Shibata T; Ohta T; Tong KI; Kokubu A; Odogawa R; Tsuta K; Asamura H; Yamamoto M; Hirohashi S
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13568-73. PubMed ID: 18757741
[TBL] [Abstract][Full Text] [Related]
14. Toward clinical application of the Keap1-Nrf2 pathway.
Suzuki T; Motohashi H; Yamamoto M
Trends Pharmacol Sci; 2013 Jun; 34(6):340-6. PubMed ID: 23664668
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous K-ras activation and Keap1 deletion cause atrophy of pancreatic parenchyma.
Hamada S; Shimosegawa T; Taguchi K; Nabeshima T; Yamamoto M; Masamune A
Am J Physiol Gastrointest Liver Physiol; 2018 Jan; 314(1):G65-G74. PubMed ID: 28971839
[TBL] [Abstract][Full Text] [Related]
16. Modulation of Nrf2/Keap1 system by Wasabi 6-methylthiohexyl isothiocyanate in ARE-mediated NQO1 expression.
Korenori Y; Tanigawa S; Kumamoto T; Qin S; Daikoku Y; Miyamori K; Nagai M; Hou DX
Mol Nutr Food Res; 2013 May; 57(5):854-64. PubMed ID: 23390006
[TBL] [Abstract][Full Text] [Related]
17. Piceatannol induces heme oxygenase-1 expression in human mammary epithelial cells through activation of ARE-driven Nrf2 signaling.
Lee HH; Park SA; Almazari I; Kim EH; Na HK; Surh YJ
Arch Biochem Biophys; 2010 Sep; 501(1):142-50. PubMed ID: 20558128
[TBL] [Abstract][Full Text] [Related]
18. Nrf2 activator via interference of Nrf2-Keap1 interaction has antioxidant and anti-inflammatory properties in Parkinson's disease animal model.
Kim S; Indu Viswanath AN; Park JH; Lee HE; Park AY; Choi JW; Kim HJ; Londhe AM; Jang BK; Lee J; Hwang H; Lim SM; Pae AN; Park KD
Neuropharmacology; 2020 May; 167():107989. PubMed ID: 32032607
[TBL] [Abstract][Full Text] [Related]
19. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
[TBL] [Abstract][Full Text] [Related]
20. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
